Y-Intercept (HK)’s Maravai LifeSciences MRVI Stock Holding History

Y-Intercept (HK)’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,113	Closed	-$37.1K	–	2007
2026 Q1	$37.1K	Buy	+13,113	New	+$44.5K	﹤0.01%	1491
2025 Q4	–	Sell	-33,775	Closed	-$96.9K	–	1847
2025 Q3	$96.9K	Buy	+33,775	New	+$86.2K	﹤0.01%	1492
2025 Q1	–	Sell	-32,359	Closed	-$176K	–	1470
2024 Q4	$176K	Buy	32,359 +19,713	+156%	+$127K	0.01%	1064
2024 Q3	$105K	Buy	+12,646	New	+$109K	0.01%	1209
2024 Q2	–	Sell	-99,813	Closed	-$865K	–	1728
2024 Q1	$865K	Buy	99,813 +42,507	+74%	+$288K	0.07%	445
2023 Q4	$375K	Buy	57,306 +33,812	+144%	+$218K	0.03%	735
2023 Q3	$235K	Buy	+23,494	New	+$258K	0.02%	859
2023 Q2	–	Sell	-50,060	Closed	-$701K	–	1556
2023 Q1	$701K	Sell	50,060 -3,116	-6%	-$44.8K	0.08%	383
2022 Q4	$761K	Buy	+53,176	New	+$837K	0.11%	284
2022 Q3	–	Sell	-17,351	Closed	-$493K	–	1163
2022 Q2	$493K	Buy	17,351 +9,596	+124%	+$304K	0.06%	430
2022 Q1	$274K	Buy	+7,755	New	+$260K	0.06%	484
2021 Q4	–	Sell	-10,216	Closed	-$501K	–	771
2021 Q3	$501K	Buy	10,216 +1,786	+21%	+$87.1K	0.09%	331
2021 Q2	$352K	Buy	+8,430	New	+$327K	0.09%	361

Other funds holding MRVI

DRP

Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

OCWP

Owl Creek Wealth Partners Denver, Colorado $342M AUM

SIC

SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

Y-Intercept (HK)'s MRVI Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Maravai LifeSciences (MRVI) in Q2 2026, closing a stake of 13,113 shares — an estimated $37.1K sold.

Y-Intercept (HK) first reported a position in MRVI in Q2 2021 and held it in 13 quarters. The position peaked at $865K in Q1 2024. 7 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Y-Intercept (HK) reported no remaining Maravai LifeSciences position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 13,113 Maravai LifeSciences shares in Q2 2026, an estimated $37.1K.
Y-Intercept (HK) first reported a position in Maravai LifeSciences in Q2 2021 and held it in 13 quarters.
Y-Intercept (HK)'s Maravai LifeSciences position peaked at $865K in Q1 2024.
7 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.